140 related articles for article (PubMed ID: 2544590)
41. Distamycin-induced inhibition of homeodomain-DNA complexes.
Dorn A; Affolter M; Müller M; Gehring WJ; Leupin W
EMBO J; 1992 Jan; 11(1):279-86. PubMed ID: 1346762
[TBL] [Abstract][Full Text] [Related]
42. Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin.
Capranico G; Jaxel C; Roberge M; Kohn KW; Pommier Y
Nucleic Acids Res; 1990 Aug; 18(15):4553-9. PubMed ID: 2167470
[TBL] [Abstract][Full Text] [Related]
43. Distamycin A and its analogs as agents for blocking of endo R. EcoRI activity.
Kuroyedov AA; Grokhovsky SL; Zhuze AL; Nosikov VV; Polyanovsky OL
Gene; 1977 Jul; 1(5-6):389-95. PubMed ID: 590744
[TBL] [Abstract][Full Text] [Related]
44. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II.
Minford J; Pommier Y; Filipski J; Kohn KW; Kerrigan D; Mattern M; Michaels S; Schwartz R; Zwelling LA
Biochemistry; 1986 Jan; 25(1):9-16. PubMed ID: 3006754
[TBL] [Abstract][Full Text] [Related]
45. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.
Capranico G; Zunino F; Kohn KW; Pommier Y
Biochemistry; 1990 Jan; 29(2):562-9. PubMed ID: 2154250
[TBL] [Abstract][Full Text] [Related]
46. Interaction of lambda cro repressor with synthetic operator OR3 studied by competition binding with minor groove binders.
Gursky GV; Surovaya AN; Kurochkin AV; Chernov BK; Volkov SK; Kirpichnikov MP
J Biomol Struct Dyn; 1992 Aug; 10(1):15-33. PubMed ID: 1329842
[TBL] [Abstract][Full Text] [Related]
47. A model for chromatin opening: stimulation of topoisomerase II and restriction enzyme cleavage of chromatin by distamycin.
Käs E; Poljak L; Adachi Y; Laemmli UK
EMBO J; 1993 Jan; 12(1):115-26. PubMed ID: 8381347
[TBL] [Abstract][Full Text] [Related]
48. Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin.
Jaxel C; Kohn KW; Pommier Y
Nucleic Acids Res; 1988 Dec; 16(23):11157-70. PubMed ID: 2849758
[TBL] [Abstract][Full Text] [Related]
49. Cleavage of DNA by mammalian DNA topoisomerase II.
Liu LF; Rowe TC; Yang L; Tewey KM; Chen GL
J Biol Chem; 1983 Dec; 258(24):15365-70. PubMed ID: 6317692
[TBL] [Abstract][Full Text] [Related]
50. Analysis of topoisomerase I and II cleavage sites on the Drosophila actin and Hsp70 heat shock genes.
Kroeger PE; Rowe TC
Biochemistry; 1992 Mar; 31(9):2492-501. PubMed ID: 1312349
[TBL] [Abstract][Full Text] [Related]
51. Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication.
Schaack J; Schedl P; Shenk T
J Virol; 1990 Jan; 64(1):78-85. PubMed ID: 2152835
[TBL] [Abstract][Full Text] [Related]
52. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
53. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.
Chen AY; Yu C; Gatto B; Liu LF
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8131-5. PubMed ID: 7690143
[TBL] [Abstract][Full Text] [Related]
54. Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions.
Adachi Y; Käs E; Laemmli UK
EMBO J; 1989 Dec; 8(13):3997-4006. PubMed ID: 2556260
[TBL] [Abstract][Full Text] [Related]
55. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.
Hong G; Kreuzer KN
Mol Cell Biol; 2000 Jan; 20(2):594-603. PubMed ID: 10611238
[TBL] [Abstract][Full Text] [Related]
56. Carbocyclic analogues of netropsin and distamycin: DNA-binding properties and inhibition of DNA topoisomerases.
Bartulewicz D; Bielawski K; Bielawska A
Arch Pharm (Weinheim); 2002 Nov; 335(9):422-6. PubMed ID: 12447915
[TBL] [Abstract][Full Text] [Related]
57. Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
Levac P; Moss T
Chromosoma; 1996 Oct; 105(4):250-60. PubMed ID: 8854885
[TBL] [Abstract][Full Text] [Related]
58. Binding of distamycin and chromomycin to human immunodeficiency type 1 virus DNA: a non-radioactive automated footprinting study.
Feriotto G; Mischiati C; Bianchi N; Passadore M; Gambari R
Eur J Pharmacol; 1995 Jul; 290(2):85-93. PubMed ID: 8575537
[TBL] [Abstract][Full Text] [Related]
59. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
60. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
